Pfizer Doubles Down In RSV By Buying ReViral
Pfizer will acquire ReViral for up to $525m, adding a Phase II antiviral for respiratory syncytial virus (RSV), complementing its own work to develop a vaccine.
Pfizer will acquire ReViral for up to $525m, adding a Phase II antiviral for respiratory syncytial virus (RSV), complementing its own work to develop a vaccine.